The National Institute of Neurological Disorders and Stroke (NINDS) at NIH is recruting patients for a six month double-blind, placebo-controlled phase 2 clinical trial to determine the safety and efficacy of idebenone administered to patients with Friedreich's Ataxia. NINDS aims to enroll 48 patients composed of children (ages 9-11) and adolescents (ages 12-17) with FA divided evenly among 4 treatment arms (placebo, "low", "intermediate", and "high" dose idebenone).